Vidarabine: Uses, Side Effects, Dosage & More

Introduction to Vidarabine

Vidarabine, also known by its chemical name 9-β-D-arabinofuranosyl adenine or ara-A, is an antiviral medication used to treat various viral infections, particularly those caused by the herpes simplex virus and varicella zoster virus. As a purine nucleoside analog, vidarabine works by interfering with viral replication, making it an effective treatment option for certain viral infections.

Uses and Indications

Vidarabine is primarily used for the treatment of herpes simplex virus infections, including genital herpes and herpes encephalitis. It is also used to treat varicella zoster virus infections, such as shingles and chickenpox. In some cases, vidarabine may be used to treat acyclovir-resistant viral infections. Additionally, vidarabine has ophthalmic uses, specifically for the treatment of eye infections caused by the herpes virus, such as herpetic keratitis.

A study published in the New England Journal of Medicine demonstrated the efficacy of vidarabine in treating herpes simplex encephalitis, with a significant reduction in mortality and morbidity compared to placebo.

Mechanism of Action

Vidarabine is a nucleoside analog that interferes with viral replication by inhibiting viral DNA polymerase. Once inside the cell, vidarabine is phosphorylated by cellular enzymes to its active triphosphate form. This active form competes with the natural nucleoside adenosine triphosphate (ATP) for incorporation into the growing viral DNA chain. When incorporated, vidarabine triphosphate prevents further elongation of the viral DNA, effectively halting viral replication.

A detailed explanation of vidarabine’s mechanism of action can be found in this research paper published in the journal Antiviral Research.

Pharmacology

Vidarabine is administered intravenously or topically as an ophthalmic ointment. When given intravenously, vidarabine is rapidly distributed throughout the body and concentrates in the kidneys, liver, and intestines. The drug is primarily eliminated unchanged in the urine, with a half-life of approximately 3.5 hours. Vidarabine exhibits linear pharmacokinetics, meaning that drug exposure increases proportionally with the administered dose.

A study published in the journal Biochemical Pharmacology provides a comprehensive overview of vidarabine’s pharmacokinetics and pharmacodynamics.

Dosage and Administration

The dosage of vidarabine depends on the specific condition being treated and the route of administration. For the treatment of herpes simplex virus infections, the typical intravenous dosage for adults is 15 mg/kg/day divided into two or three doses, administered over 12 to 24 hours for 5 to 10 days. In children, the recommended dosage is 30 mg/kg/day divided into two or three doses, administered over 12 to 24 hours for 5 to 10 days.

For ophthalmic use, vidarabine is available as a 3% ointment ( Vira-A) applied directly to the affected eye(s) five times daily until the corneal ulcer heals, and then three times daily for an additional 7 days.

A study published in the Journal of Ocular Pharmacology and Therapeutics provides evidence for the efficacy and safety of vidarabine ophthalmic ointment in the treatment of acute herpetic keratitis.

Side Effects and Tolerance

Common side effects associated with intravenous vidarabine include nausea, vomiting, diarrhea, and fever. Some patients may experience more serious adverse reactions, such as neutropenia, thrombocytopenia, or elevated liver enzymes. Ophthalmic use of vidarabine may cause temporary burning or stinging upon application, as well as mild conjunctival irritation.

Tolerance to vidarabine may develop with prolonged use, resulting in decreased efficacy. To manage tolerance, dosage adjustments or alternative antiviral medications may be considered.

Interactions

Vidarabine may interact with other medications, particularly those that affect renal function or cause nephrotoxicity. Concurrent use of vidarabine with nephrotoxic drugs, such as aminoglycosides or amphotericin B, may increase the risk of kidney damage. Additionally, vidarabine may interact with zidovudine (AZT), another antiviral medication, by reducing its efficacy.

Food does not significantly affect the absorption or efficacy of vidarabine.

Chemical Properties

Vidarabine has the molecular formula C10H13N5O4 and is a structural analog of the naturally occurring nucleoside adenosine. The chemical structure of vidarabine features a purine base ( adenine) attached to an arabinose sugar moiety. This arabinose sugar differentiates vidarabine from other nucleoside analogs, such as acyclovir, which contain a deoxyribose sugar.

Vidarabine possesses both amine and alcohol substituents, which contribute to its water solubility and ability to form salts. As a weak base, vidarabine can neutralize acids and form salts in aqueous solutions.

Historical Development and Approval

Vidarabine was discovered in the late 1960s and was initially developed as a potential treatment for cancer. However, its antiviral properties were soon recognized, and research focused on its use as an antiviral agent. In 1976, vidarabine was approved by the U.S. Food and Drug Administration (FDA) for the treatment of herpes simplex virus encephalitis. Subsequently, it gained approval for the treatment of acute herpetic keratitis and other herpes simplex virus infections.

Over time, newer and more potent antiviral medications, such as acyclovir, became available, leading to a decline in vidarabine usage. Nonetheless, vidarabine remains an important treatment option for certain viral infections, particularly those caused by acyclovir-resistant strains.

Comparison with Other Antivirals

Vidarabine is one of several antiviral medications used to treat herpes simplex virus and varicella zoster virus infections. Compared to newer antiviral agents, such as acyclovir and its prodrug valacyclovir, vidarabine has some disadvantages. Acyclovir and valacyclovir have better oral bioavailability, allowing for more convenient oral administration, while vidarabine is primarily administered intravenously. Additionally, acyclovir and valacyclovir have a more favorable side effect profile and are generally considered first-line treatments for herpes virus infections.

However, vidarabine remains an important alternative for cases of acyclovir-resistant viral strains or when other antiviral medications are contraindicated.

Clinical Studies and Efficacy

Several clinical studies have demonstrated the efficacy of vidarabine in treating various viral infections. A randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine showed that vidarabine significantly reduced mortality and morbidity in patients with herpes simplex encephalitis compared to placebo.

Another study, published in the Journal of Ocular Pharmacology and Therapeutics, demonstrated the efficacy and safety of vidarabine ophthalmic ointment in the treatment of acute herpetic keratitis. The study found that vidarabine significantly reduced the duration of viral shedding and promoted faster corneal healing compared to placebo.

Resistance

Viral resistance to vidarabine can occur, particularly with prolonged or repeated use. The most common mechanism of resistance involves mutations in the viral DNA polymerase gene, which reduce the enzyme’s affinity for vidarabine triphosphate. As a result, the mutated DNA polymerase preferentially incorporates the natural nucleoside adenosine triphosphate (ATP) instead of vidarabine triphosphate, allowing viral replication to continue.

The clinical significance of vidarabine resistance varies depending on the specific viral strain and the availability of alternative antiviral medications. In some cases, resistance to vidarabine may necessitate the use of other antiviral agents, such as acyclovir or foscarnet.

Storage and Handling

Vidarabine should be stored at room temperature, between 20°C to 25°C (68°F to 77°F), and protected from light. The drug should not be frozen or exposed to excessive heat. Vidarabine has a shelf life of approximately 2 years when stored under proper conditions.

For intravenous administration, vidarabine is typically provided as a powder for reconstitution. Once reconstituted, the solution should be used immediately or stored in the refrigerator for no more than 24 hours.

Ophthalmic Preparations

Vidarabine is available as an ophthalmic ointment ( Vira-A) for the treatment of acute herpetic keratitis. The ointment contains 3% vidarabine in a mineral oil base. To use the ophthalmic ointment, patients should apply a 1 cm ribbon of the ointment into the lower conjunctival sac of the affected eye(s) five times daily until the corneal ulcer heals, and then three times daily for an additional 7 days.

Patients should be instructed to wash their hands thoroughly before and after applying the ointment and to avoid touching the tip of the tube to the eye or any other surface to prevent contamination.

Vira-A ( Vidarabine Monohydrate)

Vira-A is the brand name for the ophthalmic ointment containing 3% vidarabine monohydrate. It is indicated for the treatment of acute herpetic keratitis, an eye infection caused by the herpes simplex virus. The most common side effects associated with Vira-A include temporary burning or stinging upon application and mild conjunctival irritation.

Patients should be advised to use Vira-A as directed by their healthcare provider and to complete the full course of treatment, even if symptoms improve. They should also be instructed to avoid wearing contact lenses during treatment and to discard any remaining ointment after the course of therapy is completed.

Antiviral Activity Spectrum

Vidarabine exhibits antiviral activity against a range of DNA viruses, primarily those belonging to the Herpesviridae family. This includes herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella zoster virus (VZV), and Epstein-Barr virus (EBV). Vidarabine is particularly effective against HSV-1, HSV-2, and VZV, making it a valuable treatment option for infections caused by these viruses.

However, vidarabine has limited or no activity against other common viruses, such as influenza, rhinovirus, or human immunodeficiency virus (HIV). Additionally, some strains of HSV and VZV may develop resistance to vidarabine, reducing its efficacy in certain cases.

Chemical Synthesis and Derivatives

Vidarabine is synthesized through a multi-step process starting with the naturally occurring nucleoside adenosine. The key step involves the selective hydroxylation of the 2′ position of the ribose sugar moiety, which is achieved using a combination of chemical and enzymatic methods. This hydroxylation step converts the ribose sugar to an arabinose sugar, yielding the desired product, vidarabine.

Several derivatives of vidarabine have been developed to improve its pharmacokinetic properties or antiviral activity. These include monophosphate and diphosphate esters of vidarabine, which exhibit enhanced cellular uptake and improved bioavailability. However, these derivatives have not been extensively studied in clinical settings.

Regulatory and Market Status

Vidarabine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute herpetic keratitis and herpes simplex virus encephalitis. It is also approved by regulatory agencies in several other countries for similar indications.

However, the market for vidarabine has significantly declined over the years due to the availability of newer, more potent antiviral medications, such as acyclovir and valacyclovir. Many healthcare providers now prefer these newer agents as first-line treatments for herpes virus infections, reserving vidarabine for cases of resistance or intolerance to other antivirals.

Replacement by More Potent Antivirals

The decline in vidarabine usage can be largely attributed to the development and widespread adoption of newer, more potent antiviral medications, particularly acyclovir and its prodrug valacyclovir. These medications offer several advantages over vidarabine, including better oral bioavailability, more convenient dosing schedules, and a more favorable side effect profile.